Chapter 30 — Further Reading

A note before the list. In this field, who funded the work is unusually load-bearing, and it is often not hidden — it is simply not noticed. Several of the most-cited papers on cosmetic peptides were conducted by the companies that sell the ingredient. That does not make them wrong. It makes them a particular kind of evidence, and reading them with the funding statement open is not cynicism, it is comprehension. Where a source below has a commercial affiliation worth knowing, it is flagged.

Search by author, title, and journal rather than by any identifier reproduced here.

Tier 1 — Start here

The 500-dalton rule, in the original. Bos, J. D., and Meinardi, M. M. H. M. "The 500 Dalton rule for the skin penetration of chemical compounds and drugs." Experimental Dermatology, 2000. Short, readable, and the source of the heuristic that organizes §30.2. Read it partly to see how modest the original claim is compared to how it is now cited — a good lesson in how a rule of thumb hardens into a law in the retelling.

The randomized trial that anchors §30.9. Hughes, M. C. B., Williams, G. M., Baker, P., and Green, A. C. "Sunscreen and prevention of skin aging: a randomized trial." Annals of Internal Medicine, 2013. A community-based randomized trial in Queensland, Australia, with skin-aging endpoints measured over four and a half years. This is the single strongest piece of evidence in the chapter for preventing visible skin aging, and it is about sunscreen rather than any peptide. Worth reading in full, because it also models what a serious trial of a topical intervention looks like.

The regulatory line, from the regulator. The United States Food and Drug Administration's public guidance pages on cosmetics — particularly the explainer distinguishing a cosmetic from a drug, and the pages on cosmetic claims and on the 2022 modernization of cosmetic regulation. Free, plainly written, and startling in how directly they state what §30.7 describes. Read the section on intended use and note that the category is set by the claim, not the formula.

A general orientation to the ingredient category. Draelos, Z. D., ed. Cosmeceuticals, in Elsevier's Procedures in Cosmetic Dermatology series. A standard clinical reference on active cosmetic ingredients, peptides among them, written for dermatologists. Useful for the vocabulary and for seeing how practicing clinicians hedge — which is usually more than the marketing does and less than the evidence warrants.

Tier 2 — Going deeper

A review of topical peptides written by dermatologic scientists rather than by sellers. Gorouhi, F., and Maibach, H. I. "Role of topical peptides in preventing or treating aged skin." International Journal of Cosmetic Science, 2009. A careful survey of the signal, carrier, and neurotransmitter-inhibiting families, notable for taking the evidence base seriously enough to describe its limits. Dated now, which is itself informative: compare its list of open questions with what has been answered since.

The primary human study most often cited for palmitoyl pentapeptide-4. Robinson, L. R., et al. "Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin." International Journal of Cosmetic Science, 2005. Industry-conducted. Read it with the §30.8 checklist in hand. It is better than much of the genre and still illustrates most of the genre's characteristic features — which is exactly why it is on this list rather than a weaker paper.

The primary study behind acetyl hexapeptide-8. Blanes-Mira, C., et al. "A synthetic hexapeptide (Argireline) with antiwrinkle activity." International Journal of Cosmetic Science, 2002. Author affiliations include the developing company. Notable for how much of the paper concerns in-vitro SNARE interference and how little concerns delivery to a neuromuscular junction in a living face. Reading it against §30.5's five-step diagram is a genuinely clarifying hour.

GHK-Cu, from its most prolific advocate. Review articles on GHK and GHK-Cu by Loren Pickart and colleagues, published across the 2000s and 2010s. Pickart has long-standing commercial involvement with copper peptide products, which you should know while reading. The reviews are the best single entry point into a genuinely large literature, and they are also advocacy. Both things are true, and holding both is the exact skill Case Study 1 is training.

The pivotal cosmetic botulinum toxin trial. Carruthers, J. A., et al. "Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines." Journal of the American Academy of Dermatology, 2002. The trial behind the cosmetic approval. Read it immediately after the Argireline paper above and the contrast will do more teaching than this chapter did — same target machinery, two completely different classes of evidence.

The earlier clinical observation. Carruthers, J. D., and Carruthers, J. A. "Treatment of glabellar frown lines with C. botulinum-A exotoxin." Journal of Dermatologic Surgery and Oncology, 1992. Short, historically important, and a nice illustration of §30.6's point that the cosmetic use was noticed while treating eye conditions.

Systematic reviews of the medical indications. Cochrane Library reviews covering botulinum toxin for cervical dystonia, for spasticity, and for chronic migraine. Read at least one in full. They demonstrate what "✅ Strong clinical evidence" actually rests on, and they will recalibrate how you read the word "study" in a cosmetic context.

Tier 3 — Technical and primary

Skin barrier structure. The body of work by Peter M. Elias and colleagues establishing the "bricks and mortar" model of the stratum corneum, and subsequent work on the organization of intercellular lipid lamellae. Dense, and the source of nearly everything in §30.2.

Transdermal delivery as an engineering discipline. Prausnitz, M. R., and Langer, R. "Transdermal drug delivery." Nature Biotechnology, 2008. A review of what it actually takes to get a molecule through skin on purpose, including the generations of enhancement technology. The best single antidote to the assumption that penetration is a formulation detail.

SNARE machinery. The primary literature on SNARE-mediated vesicle fusion, including the work recognized by the 2013 Nobel Prize in Physiology or Medicine (Rothman, Schekman, and Südhof). Essential if you want to understand why competing with SNAP-25 stoichiometrically is a much harder ask than cleaving it catalytically.

Botulinum neurotoxin mechanism. The work of Cesare Montecucco, Giampietro Schiavo, and colleagues on botulinum neurotoxin structure and its zinc-protease activity against SNARE substrates. Also, for the safety picture, the current prescribing information for any approved botulinum toxin product — which contains the boxed warning discussed in §30.6 and states plainly that units are not interchangeable between products.

European cosmetic claims regulation. Regulation (EC) No 1223/2009 on cosmetic products, and Regulation (EU) No 655/2013 laying down common criteria for cosmetic product claims. Read the common criteria annex specifically. It is a short document, it is startlingly reasonable, and comparing it with what appears on packaging in practice is an education in the gap between a rule and its enforcement.

If you only do one thing

Read the Hughes 2013 sunscreen trial, then pick up the peptide serum on your own shelf and read the back of the box.

The trial takes forty minutes and shows you what a randomized, years-long, community-based test of a topical intervention looks like, with an aging endpoint and a real control group. The box takes forty seconds.

Then ask yourself the §30.8 question about the box — was this compared against the same formulation without the peptide? — and notice that the packaging does not merely fail to answer it. It is not built to be asked.

That contrast, held for a minute or two, is the whole chapter. It does not require you to throw the serum away. It requires you to know which of the two things on your bathroom shelf is doing the work.